Overview of HIV Prevention
Summary
- The use of topical tenofovir gel evaluated as PrEP in women without HIV
- CAPRISA 004 study found that tenofovir 1% gel reduced HIV acquisition by 39% overall and by 54% among women with adherence > 80%[Abdool Karim 2010]
- VOICE and FACTS-001 trials found that topical tenofovir had no protective effect against HIV infection[Marrazzo 2015; Rees 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Biomedical Prevention